Search

Your search keyword '"Cossu Rocca M"' showing total 132 results
Start Over Author "Cossu Rocca M"
132 results on '"Cossu Rocca M"'

3. PO-1172 Sarcopenia in oropharyngeal cancer treated with curative radiotherapy: time for a tailored approach?

Author

Bergamaschi, L., primary, Zaffaroni, M., additional, Vincini, M.G., additional, Marvaso, G., additional, Volpe, S., additional, Colombo, F., additional, Bonfiglio, C., additional, Zorzi, S., additional, Cossu Rocca, M., additional, Sabbatini, A., additional, Cannillo, G., additional, Zagallo, E., additional, Ansarin, M., additional, Orecchia, R., additional, Alterio, D., additional, and Jereczek-Fossa, B., additional

Published
2023
Full Text
View/download PDF

7. PO-1088 Toxicity Profile Of 100 Oropharyngeal Cancer Patients Treated With Modern Approaches

Author

Alrerio, D., primary, Corrao, G., additional, Zorzi, S., additional, Agostini, G., additional, Marvaso, G., additional, Volpe, S., additional, Bergamaschi, L., additional, Pedone, C., additional, Franzetti, J., additional, Bonfiglio, C., additional, Camarda, A.M., additional, Tagliabue, M., additional, Cossu Rocca, M., additional, Ansarin, M., additional, and Jereczek-Fossa, B.A., additional

Published
2022
Full Text
View/download PDF

9. 862MO Gene expression profile differentiates short-term and long-term survivors with immunotherapy in patients with recurrent/metastatic head and neck cancer

Author

Bossi, P., primary, Gurizzan, C., additional, Airoldi, M., additional, Cossu Rocca, M., additional, Strojan, P., additional, Cvetka, G.K., additional, Merlano, M.C., additional, Denaro, N., additional, Caponigro, F., additional, Perri, F., additional, Argiris, A., additional, Licitra, L.F., additional, Serafini, M.S., additional, and De Cecco, L., additional

Published
2021
Full Text
View/download PDF

10. 864MO Role of geriatric assessment in tailoring treatment of locally advanced head and neck cancer: The ELDERLY study

Author

Bossi, P., primary, Esposito, A., additional, Vecchio, S., additional, Nicolai, P., additional, Tarsitano, A., additional, Mirabile, A., additional, Ursino, S., additional, Cau, M.C., additional, Bonomo, P., additional, Marengoni, A., additional, Piazza, C., additional, Maddalo, M., additional, Lorini, L., additional, Gurizzan, C., additional, Cossu Rocca, M., additional, Ripamonti, C.I., additional, Guglielmo, M., additional, and Licitra, L.F., additional

Published
2021
Full Text
View/download PDF

12. Percorso diagnostico, terapeutico e assistenziale per i tumori di testa e collo – Aggiornamento 2020 AIOCC

Author

Valentini, V., Preda, L., Ballati, F., Cicero, G., Cirillo, S., Desana, B., Farina, D., Maroldi, R., Mazziotti, S., Ravanelli, M., Vidiri, A., Licitra, L., Airoldi, M., Benasso, M., Caponigro, F., Cossu Rocca, M., Depenni, R., Ferrari, D., Merlano, M. C., Perri, F., Platini, F., Morbini, P., Orlandi, E., Alterio, D., Dell’Oca, I., Grondinelli, C., Mazzola, R., Scricciolo, M., Vanoni, V., De Felice, F., D’Onofrio, I., Franco, P., Maddalo, M., Micicchè, F., Bunkheila, F., Cianchetti, M., Iacovelli, N. A., Loreggian, L., Tonoli, S., Trignani, M., Argenone, A., D’Angelo, E., Di Rito, A., Fanetti, G., Ursino, S., Volpe, S., Belgioia, L., Dionisi, F., Lastrucci, L., Marucci, L., Molteni, M., Vischioni, B., Bacigalupo, A., Caspiani, O., Palazzi, M., Soatti, C. P., Paiar, F., Bonomo, P., Corvò, R., Merlotti, A., Musio, D., Russi, E., Sanguineti, G., De Vincentiis, M., Ansarin, M., Barzan, L., Benazzo, M., Bertolin, A., Biglioli, F., Bussi, M., Calabrese, L., Camaioni, A., Castelnuovo, P., Danesi, G., Dragonetti, A., Ferrari, S., Grandi, C., Guzzo, M., Ionna, F., Mattavelli, D., Molteni, G., Paludetti, G., Peretti, G., Pia, F., Piazza, C., Presutti, L., Ralli, M., Spriano, G., Succo, G., Tirelli, G., Remuzzi, G., and Cinquini, M.

Published
2020

13. PO-1218: Oligo Metastatic renal cell carcinoma: SBRT, if, when and how?

Author

Marvaso, G., primary, Corrao, G., additional, Oneta, O., additional, Gugliandolo, S.G., additional, Pepa, M., additional, Cecconi, A., additional, Gandini, S., additional, Piperno, G., additional, Cossu Rocca, M., additional, Verri, E., additional, Aurilio, G., additional, Corso, F., additional, Cullurà, D., additional, Rondi, E., additional, Vigorito, S., additional, Nolè, F., additional, Orecchia, R., additional, and Jereczek-Fossa, B.A., additional

Published
2020
Full Text
View/download PDF

15. EP-1160 Quantifying the impact of radiologic revision in head and neck cancer: monoinstitutional experience

Author

Alterio, D., primary, Preda, L., additional, Volpe, S., additional, Giannitto, C., additional, Riva, G., additional, Pounou Kamga, A.F., additional, Atac, M., additional, Giugliano, G., additional, Ferrari, A., additional, Marvaso, G., additional, Durante, S., additional, Arculeo, S., additional, Turturici, I., additional, Cossu Rocca, M., additional, Ansarin, M., additional, Bellomi, M., additional, Jereczek-Fossa, B.A., additional, and Orecchia, R., additional

Published
2019
Full Text
View/download PDF

16. EP-1139 Prognostic impact of hematological profile in oropharyngeal cancer treated with chemoradiotherapy

Author

Fanetti, G., primary, Rojas, D.P., additional, Marvaso, G., additional, Daniela, A., additional, Gandini, S., additional, Ferrari, A., additional, Gobitti, C., additional, Palazzari, E., additional, Coassin, E., additional, Navarria, F., additional, De Paoli, A., additional, Cossu Rocca, M., additional, Nolé, F., additional, Vaccher, E., additional, Ansarin, M., additional, Lupato, V., additional, Furlan, C., additional, Ciardo, D., additional, Orecchia, R., additional, Franchin, G., additional, and Jereczek-Fossa, B.A., additional

Published
2019
Full Text
View/download PDF

17. Clinical prognostic factors in patients (pts) with recurrent and/or metastatic (RM) head and neck carcinoma (HNC) treated with cetuximab plus chemotherapy

Author

Bossi, P., primary, Depenni, R., additional, cossu rocca, M., additional, Ferrari, D., additional, Azzarello, G., additional, Alù, M., additional, Nolè, F., additional, Codecà, C., additional, Boscolo, G., additional, Piccininni, M., additional, Cavalieri, S., additional, Pugliese, G., additional, and Licitra, L.F., additional

Published
2018
Full Text
View/download PDF

21. Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled study

Author

Bergamini, C., primary, Bergamini, C., additional, Cortinovis, D., additional, Fatigoni, S., additional, Cossu Rocca, M., additional, Fabi, A., additional, Iannace, A., additional, Emiliani, A., additional, Pessi, M.A., additional, Ripamonti, C.I., additional, Alfieri, S., additional, Granata, R., additional, Agustoni, F., additional, Bidoli, P., additional, Roila, F., additional, Nolé, F., additional, Macchi, F., additional, Michellini, L., additional, Montanaro, F., additional, and Bossi, P., additional

Published
2016
Full Text
View/download PDF

22. EP-1085: EGFR expression in head and neck cancer : does it have a role as prognostic factor in radiotherapy?

Author

Alterio, D., primary, Ferrari, A., additional, Maffini, F., additional, Marvaso, G., additional, Santoro, L., additional, Fodor, C., additional, Cossu Rocca, M., additional, Ansarin, M., additional, Dicuonzo, S., additional, Muto, M., additional, Zerini, D., additional, Chiocca, S., additional, Orecchia, R., additional, and Jereczek-Fossal, B., additional

Published
2016
Full Text
View/download PDF

23. EP-1719: Radiobiology based head & neck cancer protocol (FAMOSO) combining accelerated RT and EGFr inhibitor

Author

Alterio, D., primary, Cremonesi, M., additional, Garibaldi, C., additional, Ferrari, A.M., additional, Botta, F., additional, Ferrari, M., additional, Vigorito, S., additional, Rondi, E., additional, Cattani, F., additional, Cossu Rocca, M., additional, Strigari, L., additional, Pedicini, P., additional, Jereczek-Fossa, B.A., additional, and Orecchia, R., additional

Published
2016
Full Text
View/download PDF

24. Clinical outcome of circulating tumor cells in metastatic castration-resistant prostate cancer patients treated with docetaxel: long-term prospective single-centre study

Author

Verri, E., primary, Aurilio, G., additional, Cossu Rocca, M., additional, Sandri, M.T., additional, Pruneri, G., additional, Botteri, E., additional, Zorzino, L., additional, Cassatella, C., additional, Adamoli, L., additional, Cullurà, D., additional, De Cobelli, O., additional, Musi, G., additional, Jereczek, B., additional, Iacovelli, R., additional, and Nolè, F., additional

Published
2015
Full Text
View/download PDF

28. Strahleninduzierte akute Dysphagie : Prospektive Beobachtungsstudie an 42 Kopf-Hals-Malignompatienten.

Author

Alterio, D., Gerardi, M., Cella, L., Spoto, R., Zurlo, V., Sabbatini, A., Fodor, C., D'Avino, V., Conson, M., Valoriani, F., Ciardo, D., Pacelli, R., Ferrari, A., Maisonneuve, P., Preda, L., Bruschini, R., Cossu Rocca, M., Rondi, E., Colangione, S., and Palma, G.

Subjects
OTOLARYNGOLOGY, DEGLUTITION, DEGLUTITION disorders, ENTERAL feeding, ESOPHAGUS, GASTROSTOMY, LONGITUDINAL method, PSYCHOLOGICAL tests, RADIATION doses, RADIATION injuries, SQUAMOUS cell carcinoma, STATISTICS, TUMORS, PHARYNGEAL muscles, THERAPEUTICS, RADIOTHERAPY
Abstract

Copyright of Strahlentherapie und Onkologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2017
Full Text
View/download PDF

29. 2830 A combined modality treatment with primary chemotherapy followed by Transoral Laser Microsurgery in intermediate stage laryngeal squamous cell carcinoma: A phase II study

Author

Cossu Rocca, M., primary, Chiocca, S., additional, Maffini, F., additional, Santoro, L., additional, Cattaneo, A., additional, Alterio, D., additional, Verri, E., additional, DeBenedetto, L., additional, Massaro, M., additional, Iacovelli, R., additional, Preda, L., additional, Cullurá, D., additional, Tagliabue, M., additional, Aurilio, G., additional, Lepanto, D., additional, Nolé, F., additional, and Ansarin, M., additional

Published
2015
Full Text
View/download PDF

31. OC-006: Concomitant treatment (CRT or cetuximab/RT) with or without induction TPF in Locally Advanced head and neck

Author

Ghi, Cancer M.G., primary, Paccagnella, A., additional, Ferrari, D., additional, Foa, P., additional, Cossu Rocca, M., additional, Verri, E., additional, Morelli, F., additional, Azzarello, G., additional, D'Ambrosio, C., additional, Casanova, C., additional, Guaraldi, M., additional, Massa, E., additional, Rossetto, C., additional, Bonetti, A., additional, Siena, S., additional, Frattegiani, A., additional, Koussis, H., additional, Pieri, G., additional, Gava, A., additional, and Floriani, I., additional

Published
2015
Full Text
View/download PDF

34. E10 - Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled study

Author

Bergamini, C., Cortinovis, D., Fatigoni, S., Cossu Rocca, M., Fabi, A., Iannace, A., Emiliani, A., Pessi, M.A., Ripamonti, C.I., Alfieri, S., Granata, R., Agustoni, F., Bidoli, P., Roila, F., Nolé, F., Macchi, F., Michellini, L., Montanaro, F., and Bossi, P.

Published
2016
Full Text
View/download PDF

35. Abstract PD10-07: Hormone-Receptor Expression and Activity of Trastuzumab-Based Therapy in HER2-Positive Advanced Breast Cancer Patients

Author

Montemurro, F, primary, Rossi, V, additional, Cossu Rocca, M, additional, Martinello, R, additional, Verri, E, additional, Redana, S, additional, Adamoli, L, additional, Valabrega, G, additional, Sapino, A, additional, Aglietta, M, additional, Viale, G, additional, Goldhirsch, A, additional, and Nolè, F., additional

Published
2010
Full Text
View/download PDF

37. Cisplatin, Etoposide and Continuous Infusion Bleomycin in Patients with Testicular Germ Cell Tumors: Efficacy and Toxicity Data from a Retrospective Study

Author

Curigliano, G., primary, Spitaleri, G., additional, Magni, E., additional, Lorizzo, K., additional, De Cobelli, O., additional, Locatelli, M., additional, Fumagalli, L., additional, Adamoli, L., additional, Cossu Rocca, M., additional, Verri, E., additional, De Pas, T., additional, Jereczek-Fossa, B., additional, Martinelli, G., additional, Goldhirsch, A., additional, and Nolè, F., additional

Published
2009
Full Text
View/download PDF

39. 701 IMMUNOMAGNETIC QUANTIFICATION OF CIRCULATING TUMOUR CELLS (CTCS) AS NEW PROGNOSTIC AND PREDICTIVE FACTOR IN CASTRATION RESISTANT PROSTATE CANCER (CRPC): PRELIMINARY RESULTS

Author

Cossu, Rocca M., primary, Verri, E., additional, Sandri, M.T., additional, Marenghi, C., additional, Botteri, E., additional, Adamoli, L., additional, Curigliano, G., additional, De Cobelli, O., additional, Rocco, B., additional, Zorzino, L., additional, Cassatella, M.C., additional, and Nolè, F., additional

Published
2009
Full Text
View/download PDF

44. Brain metastases in patients with advanced breast cancer

Author

Sanna, G., Franceschelli, L., Rotmensz, N., Botteri, E., Adamoli, L., Cristina Marenghi, Munzone, E., Cossu Rocca, M., Verri, E., Minchella, I., Medici, M., Catania, C., Magni, E., Goldhirsch, A., and Nolè, F.

46. Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center

Author

Barbara Alicja Jereczek-Fossa, Samuele Frassoni, Giuseppe Curigliano, D. Cullurà, Emanuela Omodeo Salè, Vincenzo Bagnardi, Franco Orsi, Gennaro Musi, M Milani, Franco Nolè, Roberta Mascia, Gaetano Aurilio, Maria Cossu Rocca, Ottavio De Cobelli, Elena Verri, Aurilio, G, Verri, E, Frassoni, S, Bagnardi, V, Cossu Rocca, M, Cullura, D, Milani, M, Mascia, R, Curigliano, G, Orsi, F, Jereczek-Fossa, B, Musi, G, Omodeo Sale, E, De Cobelli, O, and Nole, F

Subjects
Adult, Lung Diseases, Male, Cancer Research, medicine.medical_specialty, Adolescent, Pulmonary toxicity, medicine.medical_treatment, Cancer Care Facilities, Neutropenia, Gastroenterology, Drug Administration Schedule, Bleomycin, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Germ-Cell Tumors Treated, Humans, 030212 general & internal medicine, Etoposide, Retrospective Studies, Chemotherapy, business.industry, Neoplasms, Germ Cell and Embryonal, medicine.disease, Chemotherapy regimen, Regimen, Oncology, 030220 oncology & carcinogenesis, Germ cell tumors, Cisplatin, business, Febrile neutropenia, medicine.drug
Abstract

Objectives Bleomycin, etoposide, and cisplatin (BEP) is the most common and successful chemotherapy regimen for germ-cell tumor (GCT) patients, accompanied by a bleomycin-induced dose-dependent lung toxicity in certain patients. In an attempt to reduce bleomycin-toxicity, we developed a modified-BEP (mBEP) regimen. Materials and methods Between August 2008 and February 2018, 182 unselected mainly testicular GCT patients (39 with adjuvant purpose and 143 with curative purpose) received a tri-weekly 5-day hospitalization schedule with bleomycin 15 U intravenous (IV) push on day 1 and 10 U IV continuous infusion over 12 hours on days 1 to 3, cisplatin 20 mg/m IV, and etoposide 100 mg/m IV on days 1 to 5. Pulmonary toxicity was assessed through chest computed tomography scan and clinical monitoring. Results Median number of mBEP cycles was 3 (range: 1 to 4). In the curative setting, according to the International Germ Cell Cancer Collaborative Group (IGCCCG) prognostic system, 112, 21, and 9 patients had good-risk, intermediate-risk, and poor-risk class, respectively; 66 (46%) patients had complete response (CR), 67 (47%) had partial response (52 of whom became CR afterwards), 6 (4%) had stable disease (that in 3 became CR afterwards), 3 (2%) progressed, and 1 (1%) died of brain stroke. At a median follow-up of 2.67 years (interquartile range: 1.23-5.00 y), 1 and 5-year overall survival and progression-free survival were 99% and 95%, and 90% and 88%, respectively. In the entire patient population, there was grade 3/4 neutropenia in 92 patients (51%), febrile neutropenia in 11 patients (6%), grade 1/2 nausea in 74 patients (41%), and no death due to pulmonary toxicity. Conclusion In GCT patients, our mBEP-schedule would suggest an effective treatment modality without suffering meaningful pulmonary toxicity.

Published
2020

47. A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin

Author

Francesco Agustoni, Cristiana Bergamini, F. Montanaro, Paolo Bossi, Diego Cortinovis, P. Bidoli, Fabio Macchi, Roberta Granata, Franco Nolè, M.A. Pessi, Carla B. Ripamonti, Salvatore Alfieri, M. Cossu Rocca, Alessandra Fabi, S. Fatigoni, Fausto Roila, P. Seminara, L. Michellini, Bossi, P, Cortinovis, D, Fatigoni, S, Cossu Rocca, M, Fabi, A, Seminara, P, Ripamonti, C, Alfieri, S, Granata, R, Bergamini, C, Agustoni, F, Bidoli, P, Nolè, F, Pessi, M, Macchi, F, Michellini, L, Montanaro, F, and Roila, F

Subjects
Male, medicine.medical_specialty, Vomiting, ginger, medicine.drug_class, Nausea, Ginger Extract, medicine.medical_treatment, Population, Scientific evidence, Antineoplastic Agents, Placebo, Herbal therapies, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Neoplasms, Internal medicine, medicine, Humans, Antiemetic, chemotherapy-induced nausea and vomiting, 030212 general & internal medicine, Cancer, Dietary supplementation, education, education.field_of_study, Chemotherapy, Dose-Response Relationship, Drug, Plant Extracts, business.industry, Hematology, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Anesthesia, Antiemetics, Female, Cisplatin, Herbal therapie, medicine.symptom, business, Chemotherapy-induced nausea and vomiting
Abstract

Background The activity of ginger in the management of chemotherapy-induced nausea and vomiting (CINV) has been suggested, but design inadequacies, heterogeneity of the population, small numbers and poor quality of tested products limit the possibility to offer generalizable results. Patients and methods We conducted a randomized, double-blind, placebo-controlled, multicenter study in patients planned to receive ≥2 chemotherapy cycles with high dose (>50 mg/m2) cisplatin. Patients received ginger 160 mg/day (with standardized dose of bioactive compounds) or placebo in addition to the standard antiemetic prophylaxis for CINV, starting from the day after cisplatin administration. CINV was assessed through daily visual-analogue scale and Functional Living Index Emesis questionnaires. The main objective was protection from delayed nausea; secondary end points included intercycle nausea and nausea anticipatory symptoms. Results In total, 121 patients received ginger and 123 placebo. Lung (49%) and head and neck cancer (HNC; 35%) were the most represented tumors. No differences were reported in terms of safety profile or compliance. The incidence of delayed, intercycle and anticipatory nausea did not differ between the two arms in the first cycle and second cycle. A benefit of ginger over placebo in Functional Living Index Emesis nausea score differences (day 6−day 1) was identified for females (P = 0.048) and HNC patients (P = 0.038). Conclusions In patients treated with high-dose cisplatin, the daily addition of ginger, even if safe, did not result in a protective effect on CINV. The favorable effect observed on nausea in subgroups at particular risk of nausea (females; HNC) deserves specific investigation.

Published
2017

48. A Transcriptomic Analysis of Laryngeal Dysplasia.

Author

Maffini F, Lepanto D, Chu F, Tagliabue M, Vacirca D, De Berardinis R, Gandini S, Vignati S, Ranghiero A, Taormina S, Rappa A, Cossu Rocca M, Alterio D, Chiocca S, Barberis M, Preda L, Pagni F, Fusco N, and Ansarin M

Subjects
Humans, Gene Expression Profiling methods, Laryngeal Neoplasms genetics, Laryngeal Neoplasms pathology, High-Throughput Nucleotide Sequencing, Transcriptome
Abstract

This article describes how the transcriptional alterations of the innate immune system divide dysplasias into aggressive forms that, despite the treatment, relapse quickly and more easily, and others where the progression is slow and more treatable. It elaborates on how the immune system can change the extracellular matrix, favoring neoplastic progression, and how infections can enhance disease progression by increasing epithelial damage due to the loss of surface immunoglobulin and amplifying the inflammatory response. We investigated whether these dysregulated genes were linked to disease progression, delay, or recovery. These transcriptional alterations were observed using the RNA-based next-generation sequencing (NGS) panel Oncomine Immune Response Research Assay (OIRRA) to measure the expression of genes associated with lymphocyte regulation, cytokine signaling, lymphocyte markers, and checkpoint pathways. During the analysis, it became apparent that certain alterations divide dysplasia into two categories: progressive or not. In the future, these biological alterations are the first step to provide new treatment modalities with different classes of drugs currently in use in a systemic or local approach, including classical chemotherapy drugs such as cisplatin and fluorouracile, older drugs like fenretinide, and new checkpoint inhibitor drugs such as nivolumab and pembrolizumab, as well as newer options like T cell therapy (CAR-T). Following these observed alterations, it is possible to differentiate which dysplasias progress or not or relapse quickly. This information could, in the future, be the basis for determining a close follow-up, minimizing surgical interventions, planning a correct and personalized treatment protocol for each patient and, after specific clinical trials, tailoring new drug treatments.

Published
2024
Full Text
View/download PDF

49. Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.

Author

Serafini MS, Cavalieri S, Licitra L, Pistore F, Lenoci D, Canevari S, Airoldi M, Cossu Rocca M, Strojan P, Kuhar CG, Merlano M, Perrone F, Vingiani A, Denaro N, Perri F, Argiris A, Gurizzan C, Ghi MG, Cassano A, Allegrini G, Bossi P, and De Cecco L

Subjects
Humans, Squamous Cell Carcinoma of Head and Neck drug therapy, Squamous Cell Carcinoma of Head and Neck genetics, Platinum, Biomarkers, Nivolumab therapeutic use, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms genetics
Abstract

Background: Immune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. The reported benefit in clinical trials is variable and heterogeneous. Our study aims at exploring and comparing the predictive role of gene-expression signatures with classical biomarkers for immunotherapy-treated R/M HNSCC patients in a multicentric phase IIIb trial., Methods: Clinical data were prospectively collected in Nivactor tiral (single-arm, open-label, multicenter, phase IIIb clinical trial in platinum-refractory HNSCC treated with nivolumab). Findings were validated in an external independent cohort of immune-treated HNSCC patients, divided in long-term and short-term survivors (overall survival >18 and <6 months since the start of immunotherapy, respectively). Pretreatment tumor tissue specimen from immunotherapy-treated R/M HNSCC patients was used for PD-L1 (Tumor Proportion Score; Combined Positive Score (CPS)) and Tumor Mutational Burden (Oncopanel TSO500) evaluation and gene expression profiling; classical biomarkers and immune signatures (retrieved from literature) were challenged in the NIVACTOR dataset., Results: Cluster-6 (Cl6) stratification of NIVACTOR cases in high score (n=16, 20%) and low score (n=64, 80%) demonstrated a statistically significant and clinically meaningful improvement in overall survival in the high-score cases (p=0.00028; HR=4.34, 95% CI 1.84 to 10.22) and discriminative ability reached area under the curve (AUC)=0.785 (95% CI 0.603 to 0.967). The association of high-score Cl6 with better outcome was also confirmed in: (1) NIVACTOR progression-free survival (p=4.93E-05; HR=3.71, 95% CI 1.92 to 7.18) and objective-response-rate (AUC=0.785; 95% CI 0.603 to 0.967); (2) long survivors versus short survivors (p=0.00544). In multivariate Cox regression analysis, Cl6 was independent from Eastern Cooperative Oncology Group performance status, PDL1-CPS, and primary tumor site., Conclusions: These data highlight the presence of underlying biological differences able to predict survival and response following treatment with immunotherapy in platinum-refractory R/M HNSCC that could have translational implications improving treatment selection., Trial Registration Number: EudraCT Number: 2017-000562-30., Competing Interests: Competing interests: No, there are no competing interests., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2024
Full Text
View/download PDF

50. Penile-Sparing Surgery for Tumour Recurrence after Previous Glansectomy/Partial Penectomy: Treatment Feasibility and Oncological Outcomes.

Author

Musi G, Molinari F, Mistretta FA, Piccinelli ML, Guzzo S, Tozzi M, Lievore E, Blezien O, Fontana M, Cioffi A, Cullurà D, Verri E, Cossu Rocca M, Nolè F, Ferro M, de Cobelli O, and Luzzago S

Abstract

We tested the feasibility and oncological outcomes after penile-sparing surgery (PSS) for local recurrent penile cancer after a previous glansectomy/partial penectomy. We retrospectively analysed 13 patients (1997-2022) with local recurrence of penile cancer after a previous glansectomy or partial penectomy. All patients underwent PSS: circumcision, excision, or laser ablation. First, technical feasibility, treatment setting, and complications (Clavien-Dindo) were recorded. Second, Kaplan-Meier plots depicted overall and local recurrences over time. Overall, 11 (84.5%) vs. 2 (15.5%) patients were previously treated with glansectomy vs. partial penectomy. The median (IQR) time to disease recurrence was 56 (13-88) months. Six (46%) vs. two (15.5%) vs. five (38.5%) patients were treated with, respectively, local excision vs. local excision + circumcision vs. laser ablation. All procedures, except one, were performed in an outpatient setting. Only one Clavien-Dindo 2 complication was recorded. The median follow-up time was 41 months. Overall, three (23%) vs. four (30.5%) patients experienced local vs. overall recurrence, respectively. All local recurrences were safely treated with salvage surgery. In conclusion, we reported the results of a preliminary analysis testing safety, feasibility, and early oncological outcomes of PSS procedures for patients with local recurrence after previous glansectomy or partial penectomy. Stronger oncological outcomes should be tested in other series to optimise patient selection.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results